103 related articles for article (PubMed ID: 2190582)
1. Antitumoral and other biomedical activities of synthetic ether lysophospholipids.
Munder PG; Westphal O
Chem Immunol; 1990; 49():206-35. PubMed ID: 2190582
[No Abstract] [Full Text] [Related]
2. Studies of the antitumor activity of (2-alkoxyalkyl)- and (2-alkoxyalkenyl)phosphocholines.
Bonjouklian R; Phillips ML; Kuhler KM; Grindey GB; Poore GA; Schultz RM; Altom MG
J Med Chem; 1986 Dec; 29(12):2472-7. PubMed ID: 3783607
[TBL] [Abstract][Full Text] [Related]
3. Activation of mouse peritoneal macrophages by lysophospholipids and ether derivatives of neutral lipids and phospholipids.
Yamamoto N; Ngwenya BZ
Cancer Res; 1987 Apr; 47(8):2008-13. PubMed ID: 2950993
[TBL] [Abstract][Full Text] [Related]
4. [Ether lipids--a new structural class of antineoplastic compounds].
Kovar A; Grauer C; Zimmermann W
Pharmazie; 1994 Jul; 49(7):471-9. PubMed ID: 8073056
[No Abstract] [Full Text] [Related]
5. Anti-tumor action of alkyl-lysophospholipids (Review).
Berdel WE; Bausert WR; Fink U; Rastetter J; Munder PG
Anticancer Res; 1981; 1(6):345-52. PubMed ID: 7046622
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C--a novel target for rational anti-cancer drug design?
Gescher A; Dale IL
Anticancer Drug Des; 1989 Aug; 4(2):93-105. PubMed ID: 2679620
[No Abstract] [Full Text] [Related]
7. Synthesis of ether-linked analogues of lysophosphatidate and their effect on the proliferation of human epithelial cancer cells in vitro.
Ashagbley A; Samadder P; Bittman R; Erukulla RK; Byun HS; Arthur G
Anticancer Res; 1996; 16(4A):1813-8. PubMed ID: 8712705
[TBL] [Abstract][Full Text] [Related]
8. Studies on various parameters influencing leukemic cell destruction by alkyl-lysophospholipids.
Andreesen R; Modolell M; Oepke GH; Common H; Löhr GW; Munder PG
Anticancer Res; 1982; 2(1-2):95-100. PubMed ID: 7114806
[TBL] [Abstract][Full Text] [Related]
9. Generation of tumorcidal macrophages and direct selective destruction of tumor cells by membrane active adjuvants.
Munder PG; Modolell M; Andreesen R; Berdel W; Pahlke W; Oepke R; Westphal O
Prog Clin Biol Res; 1983; 132B():393-402. PubMed ID: 6634762
[No Abstract] [Full Text] [Related]
10. Mitoxantrone in multiple sclerosis.
Neuhaus O; Kieseier BC; Hartung HP
Adv Neurol; 2006; 98():293-302. PubMed ID: 16400840
[No Abstract] [Full Text] [Related]
11. Parallel fragment assembly strategy towards multiple-ether mimicry of anticancer annonaceous acetogenins.
Jiang S; Li Y; Chen XG; Hu TS; Wu YL; Yao ZJ
Angew Chem Int Ed Engl; 2004 Jan; 43(3):329-34. PubMed ID: 14705089
[No Abstract] [Full Text] [Related]
12. Antineoplastic activity of synthetic lysophospholipid analogs.
Berdel WE
Blut; 1982 Feb; 44(2):71-8. PubMed ID: 7059692
[No Abstract] [Full Text] [Related]
13. Can oxysterols have some interest in the treatment of tumors?
Beck JP
Prog Clin Biol Res; 1990; 348():71-93. PubMed ID: 2201035
[No Abstract] [Full Text] [Related]
14. [Ether lipids--synthesis and application in tumor therapy].
Zeisig R; Arndt D; Brachwitz H
Pharmazie; 1990 Nov; 45(11):809-18. PubMed ID: 2100332
[No Abstract] [Full Text] [Related]
15. Synthesis and structure-activity relationship studies of cytotoxic ester and ether anhydrovinblastine derivatives.
Zhang HK; Shao Y; Ding H; Hu LH
J Nat Prod; 2008 Oct; 71(10):1669-76. PubMed ID: 18771244
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
Reichardt HM; Gold R; Lühder F
Expert Rev Neurother; 2006 Nov; 6(11):1657-70. PubMed ID: 17144780
[TBL] [Abstract][Full Text] [Related]
17. Morphological effects of an antitumor agent on human esophageal carcinoma cells in vitro.
Maistry L; Robinson KM; Evers P; Munder PG; Andreesen R
Scan Electron Microsc; 1980; (3):109-14. PubMed ID: 7191137
[No Abstract] [Full Text] [Related]
18. [New synthetic cytotoxic and antitumoral agents derived from aristolochic acid, an antitumoral nitrophenanthrenic acid extracted from Aristolochiaceae].
Viel C; Doré JC
Farmaco Sci; 1972 Apr; 27(4):257-312. PubMed ID: 5023999
[No Abstract] [Full Text] [Related]
19. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
Talmadge JE; Herberman RB
Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
[No Abstract] [Full Text] [Related]
20. The place of pharmacology in cancer medicine.
Capizzi RL
Semin Oncol; 1977 Jun; 4(2):131-3. PubMed ID: 877598
[No Abstract] [Full Text] [Related]
[Next] [New Search]
